Jim Cramer's 'Mad Money' CEO Chats: Edwards Lifesciences and Galena Biopharma

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.

NEW YORK (TheStreet) -- Every night, Jim Cramer sits down with CEOs and executives on his "Mad Money" show to discuss their business, the economy, politics and more. Today we look back at his recent interviews with Michael Mussallem, chairman and CEO of Edwards Lifesciences (EW), and Dr. Mark Ahn, president and CEO of Galena Biopharma (GALE), representing both the big and small sides of health care in America.

These are excerpts from Cramer's 'Mad Money' Recap, originally published on Jan. 15 and Jan. 16, 2014.

Executive Decision: Michael Mussallem

For his second "Executive Decision" segment, Cramer spoke with Michael Mussallem, chairman and CEO of Edwards Lifesciences, one of last year's laggards that is now up 7% so far in 2014.

Mussallem commented on his company's recent legal win against Medtronic (MDT) for patent infringement. He called the decision a big win for his team as it's the second time a jury have found in the company's favor.

Mussallem continued that Edwards has always been an innovator, inventing in the technology that allows heart value implants without the need for open-heart surgery.

When asked why the company lowered expectations for Wall Street analysts, Mussallem said there was never a question if competition was coming, only when, and now that its here, it's only prudent to be realistic.

That said, Mussallem touted his company's new "Sapien 3" technology as the next generation of treatments, something the competition will not be able to mimic for quite some time.

If you liked this article you might like

Edwards Lifesciences: Cramer's Top Takeaways

Don't Let Stock Picking Scare You: Cramer's 'Mad Money' Recap (Wednesday 7/19/17)

Hold on Concert's Hair Loss Trials Pushes Shares Down 10%

Edwards Lifesciences Is Not Skipping A Beat

Canaccord Says Edwards Lifesciences Is Its Favorite Med Tech Stock